Closing remarks to the symposium: Isozyme research

IMANA-Hofstra Ethics Symposium: Closing Remarks

jima.imana.org First, I would like to congratulate Dr. Hossam Fadel and Professor Daniel Varisco for organizing this informative and educational two-day conference. I wanted to share a brief snapshot of the conference from my perspective. The conference started with a discussion on brain death. We found a lot of commonalities among the Abrahamic faiths, and the consensus was that brain death is...

Closing Remarks.

Closing Remarks.

About twenty years ago, the leaders of the National Cancer Institute (NCI) decided to start a new branch in the Clinical Oncology Program of the Division of Cancer Treatment. That new entity was named the Clinical Pharmacology Branch (CPB), and its first leader was a brilliant, young, promising investigator named Bruce A. Chabner. Chabner was educated at Yale and Harvard, and appeared to have a...

Closing remarks

DMARDs = disease-modifying antirheumatic drugs; NSAIDs = non-steroidal anti-inflammatory drugs; RA = rheumatoid arthritis; TNF = tumor necrosis factor. Introduction The past decade has been marked by significant advances in rheumatology, including a better understanding of the pathophysiology of rheumatic diseases and the addition of agents to the therapeutic armamentarium. Studies in cell biol...

Closing Remarks

Well we’ve had a rich and interesting day. I can’t possibly do it justice. But I have been asked to make a few minutes of final remarks. I assure you this was not my idea. And by my clock, I have minus eight minutes. So I’ll try to be very quick. But my assignment as I understood is it to try and extract from today’s presentations and discussions and the posters some discernable themes in the w...